Innovation all for the patients

CHUGAI

Roche A member of the Roche group

CHMP Recommends Expansion of EU Label for Hemlibra to Include People with Moderate Hemophilia A

TOKYO, December 19, 2022 -- Chugai Pharmaceutical Co., Ltd. (TOKYO: 4519) announced that Roche issued a press release on the anti-coagulation factor IXa/X humanized bispecific monoclonal antibody/coagulation factor VIII substitute Hemlibra® [generic name: emicizumab (genetical recombination)]. The European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) recommended to approve the additional indication of Hemlibra for moderate hemophilia A.

Please refer to the link below for details:

- CHMP recommends expansion of EU label for Hemlibra to include people with moderate haemophilia A
  https://www.roche.com/media/releases/med-cor-2022-12-16

###

CHUGAI PHARMACEUTICAL CO., LTD. Corporate Communications Dept.
1-1, Nihonbashi-Muromachi 2-chome, Chuo-ku Tokyo, 103-8324 Japan
Media Relations Group TEL:+81-(0)3-3273-0881 E-mail:pr@chugai-pharm.co.jp
Investor Relations Group TEL:+81-(0)3-3273-0554 E-mail:ir@chugai-pharm.co.jp